Infect Chemother.  2017 Jun;49(2):130-134. 10.3947/ic.2017.49.2.130.

Is the Initial Size of Tuberculous Lymphadenopathy associated with Lymph Node Enlargement during Treatment?

• Seol YJ
• Park SY
• Yu SN
• Kim T
• Lee EJ
• Jeon MH
• Choo EJ
• Kim TH

• KMID: 2383934
• DOI: http://doi.org/10.3947/ic.2017.49.2.130

Abstract

There are little data on the changes in lymph node (LN) size during the treatment of tuberculous lymphadenopathy (TB LAP). This study aimed to provide data on LN changes during treatment. Between March 2014 and December 2015, 20 patients who were diagnosed with cervical TB LAP were enrolled. LN enlargement within two months (50%, 4/8 vs. 8.3%, 1/12; P = 0.04) was more frequently observed in patients with initial LN size ≥ 7.5 cm². Enlarged LNs were excised in three patients owing to pain and fistula formation. Initial LN size may be associated with LN enlargement during treatment.

Keyword

Tuberculosis; Lymphadenopathy; Outcome

MeSH Terms

Fistula
Humans
Lymph Nodes*
Lymphatic Diseases*
Tuberculosis

Figure

• 

  Figure 1 Treatment outcomes of tuberculous lymphadenopathy according to initial lymph node size. Five (25%) patients received LN excision for the following reasons: athree for complaints associated with pain and fistula, bone due to a request for remaining LN excision, and cone for diagnostic purposes. LN enlargement during treatment was more frequently observed in patients with initial LN size ≥ 7.5 cm2, compared to those < 7.5 cm2 (50%, 4/8 vs. 8.3%, 1/12; P = 0.04). LN, lymph node.

Reference

1. Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2015; 78:47–55.

2. Korean Society for AIDS. The 2015 clinical guidelines for the treatment and prevention of opportunistic infections in HIV-infected Koreans: guidelines for opportunistic infections. Infect Chemother. 2016; 48:54–60.

3. Cho OH, Park KH, Kim T, Song EH, Jang EY, Lee EJ, Chong YP, Choi SH, Lee SO, Woo JH, Kim YS, Kim SH. Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis. J Infect. 2009; 59:56–61.

4. Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. Medicine (Baltimore). 2005; 84:350–362.

5. Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD, Choe KW. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. Arch Intern Med. 2007; 167:2255–2259.

6. Kanjanopas K, Siripan N, Phoophitphong R. Tuberculous cervical lymphadenopathy and the role of surgical treatment. Southeast Asian J Trop Med Public Health. 2014; 45:1419–1424.

7. Joo YH, Hwang SH, Seo JH, Kang JM. Treatment assessment based on computerized lymph node volume and ratio of necrotic area in tuberculous cervical lymphadenitis. Auris Nasus Larynx. 2012; 39:402–406.

8. Park KH, Lee MS, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Incidence and outcomes of paradoxical lymph node enlargement after anti-tuberculosis therapy in non-HIV patients. J Infect. 2013; 67:408–415.

9. Jindal SK, Aggarwal AN, Gupta D, Ahmed Z, Gupta KB, Janmeja AK, Kashyap S, Singh M, Mohan A, Whig J. Tuberculous lymphadenopathy: a multicentre operational study of 6-month thrice weekly directly observed treatment. Int J Tuberc Lung Dis. 2013; 17:234–239.